Inhibikase Therapeutics IKT
NASDAQ IKT
$2.50 -0.02 (-0.79%)
As of: Sep 4, 2026 · 3:59 PM EDT

Inhibikase Therapeutics (IKT) FCF Margin (QoQ) (2020 - 2023)

Analysis

Inhibikase Therapeutics (IKT) FCF Margin (QoQ) (2020 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Inhibikase Therapeutics 435.56 Mn 276.54 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -34.42 Bn
Sep 30, 2023 -123,734.00
Jun 30, 2023 533,428.00
Mar 31, 2023 -366,133.00
Dec 31, 2022 7.27 Mn
Sep 30, 2022 -1.18 Mn
Jun 30, 2022 -5.79 Mn
Mar 31, 2022 20.21 Mn
Dec 31, 2021 -21.01 Mn
Sep 30, 2021 -30,360.00
Jun 30, 2021 -3,196.00
Mar 31, 2021 27,584.00
Dec 31, 2020 -75,583.00
Sep 30, 2020 20,174.00
Jun 30, 2020 9,300.00